NEW YORK, NY, USA I 13, 2025 I Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel ...
Hosted on MSN24d
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame. The ...
Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...
Incyte Corporation INCY reported fourth-quarter 2024 adjusted earnings of $1.43 per share, which missed the Zacks Consensus ...
Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...
But Seneschal and colleagues were not discouraged overall. The trial "highlighted the efficacy of combining the JAK1/JAK2 inhibitor baricitinib with narrowband UV-B in the treatment of adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback